
Effective strategies to improve access to treatment and care | Global Policy and Access Summit 2021
In this session from the Global Policy and Access Summit, Dawn Rotellini, Bradley Rayner, Declan Noone and Durhane Wong-Rieger, will
Year: 2025
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The global bleeding disorders community reached a major milestone in 2025, as the World Health Organization updated both its Essential Medicines List (EML) and Essential Medicines List for Children (EMLc) to align with modern international guidelines for hemophilia and von Willebrand disease. Led by the World Federation of Hemophilia (WFH), this achievement reflects two years of coordinated global advocacy, scientific collaboration, and direct engagement with the WHO. These updates will help improve equitable access to safer and more effective therapies for people with bleeding disorders worldwide.
In this video, watch a WFH expert panel discussion held in November 2025, where global stakeholders reflect on the significance of these landmark changes and what they mean for patients, clinicians, and health systems worldwide.
The panel is chaired by David Page, Consultant, Safety and Supply of Coagulation Products, Canadian Hemophilia Society and WFH Coagulation Product Safety, Supply and Access (CPSSA) Committee Member, includes the following speakers (in order of their seating in the video, left to right): Alain Baumann, CEO, WFH; Glenn Pierce, MD, PhD, WFH Vice President, Medical; Salome Mekhuzla, Director, Global Development, WFH; Radek Kaczmarek, Chair of the Coagulation Product Safety, Supply and Access (CPSSA) Committee, WFH; Mark W. Skinner, Board Member, WFH USA; Maria Elisa Mancuso, MD; Brian O’Mahony, Chief Executive, Irish Haemophilia Society; and Cesar Garrido, President, WFH.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

In this session from the Global Policy and Access Summit, Dawn Rotellini, Bradley Rayner, Declan Noone and Durhane Wong-Rieger, will

In this session from the Global Policy and Access Summit, Dawn Rotellini, Mark Skinner, Jamie O’Hara and David Page will

How is the pandemic impacting global healthcare systems around the world? What will the “new normal” be? In this opening

In this session from the Global Policy and Access Summit, Glenn Pierce, MD (WFH VP Medical), will moderate a panel

In this session from the Global Policy and Access Summit, Mukesh Garodia, Brian O’Mahony, Yuri Zhulyov, Margarita Elizabeth Garcia Gonzalez

The COVID-19 pandemic has significantly affected the bleeding disorders community, and many countries have seen their governments shift their focus